0001193125-21-023611.txt : 20210201 0001193125-21-023611.hdr.sgml : 20210201 20210201064058 ACCESSION NUMBER: 0001193125-21-023611 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210201 DATE AS OF CHANGE: 20210201 EFFECTIVENESS DATE: 20210201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Prevail Therapeutics Inc. CENTRAL INDEX KEY: 0001714798 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-38939 FILM NUMBER: 21574278 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET, SUITE 940 CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 917-336-9310 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET, SUITE 940 CITY: NEW YORK STATE: NY ZIP: 10016 15-12B 1 d106556d1512b.htm 15-12B 15-12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-38939

 

 

PREVAIL THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

 

Lilly Corporate Center

Indianapolis, Indiana 46285

Telephone: (917) 336-9310

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, $0.0001 par value per share

(Title of each class of securities covered by this Form)

None

(Title of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

   ☒

Rule 12g-4(a)(2)

   ☐

Rule 12h-3(b)(1)(i)

   ☒

Rule 12h-3(b)(1)(ii)

   ☐

Rule 15d-6

   ☐

Rule 15d-22(b)

   ☐

Approximate number of holders of record as of the certification or notice date: One

Pursuant to the requirements of the Securities Exchange Act of 1934, Prevail Therapeutics Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: February 1, 2021

  

Prevail Therapeutics Inc.

 

By:

  

/s/ Kenneth L. Custer

 

Name:

  

Kenneth L. Custer

 

Title:

  

President